

## Pharma IPR 2021 discuss ways to create efficient IP framework

24 September 2021 | News

**An efficient IP framework globally will help to bolster the potential of growth, investments, and collaboration amid crises**



Informa Pharma Intelligence, the Knowledge Partner of Pharma IPR 2021, concluded the 10th Annual Pharma IPR India Conference in congregation with Informa Pharma Intelligence. The theme for the conference was 'Ideate and Innovate.' The event witnessed an exchange of thoughts to create an efficient IP framework globally to bolster the potential of growth, investments, and collaboration amid crises.

Poornachandra Tejasvi, Senior Director, Emerging Markets, India, at Informa Pharma Intelligence said, "The Pharma IPR India Conference is an innovative platform to motivate researchers and IP professionals to explore new areas of pharma and biotech innovation, with modern intellectual property strategies, policies, and strong protection are extremely essential, especially amidst the crisis we are in."

Yogesh Mudras, MD, Informa Markets in India, said, "Recent challenges over patents for varied newer drugs has emphasised that advancement is still required in balancing the opposing forces of innovation through the protection of IP rights, versus the provision of affordable drugs for the emerging geographical regions across the globe. IP is the backbone to ensure the development of new drugs and is extremely vital to improvise patient care, spurring economic growth and intensifying the innovation economy. To motivate researchers to explore new areas of medical innovation, modern IP systems and strong protections are crucial."

This conference created a common platform for all key stakeholders, IP/Patent leaders from across India and law firms from across the globe. Based on Informa Pharma Intelligence's 'Indian Biosimilars Report', India leads the way with 127 products, which is the highest number of approved biosimilars compared to other major regions. This is expected to grow further and is likely to shape the next decade for the Indian biosimilars market through intensive portfolio management decisions, pricing, manufacturing prospects, clinical trials and government support.

The notable members of the advisory board and speakers were Prathiba M Singh, Justice, Delhi High Court, Jacqueline Wright Bonilla, Deputy Chief Administrative Patent Judge, Patent Trial and Appeal Board (PTAB), US Patent and Trademark Office.